Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019002 | 1.00 | MAPK14 (0.38) | MAPK14SMN1; SMN2ALDH1A1HPGDSCN9A | |
| SCHEMBL4837025 | 0.88 | MAPK14 (0.37) | MAPK14SMN1; SMN2ALDH1A1HPGDSCN9A | |
| SCHEMBL14018996 | 0.88 | MAPK14 (0.37) | MAPK14SMN1; SMN2ALDH1A1HPGDSCN9A | |
| SCHEMBL4837496 | 0.87 | MAPK14 (0.42) | MAPK14MAPK11 | |
| SCHEMBL14018995 | 0.87 | MAPK14 (0.42) | MAPK14MAPK11 | |
| SCHEMBL14019012 | 0.85 | MAPK14 (0.41) | MAPK14MAPK11 | |
| SCHEMBL4842888 | 0.85 | MAPK14 (0.41) | MAPK14MAPK11 | |
| SCHEMBL4842380 | 0.84 | MAPK14 (0.39) | MAPK14ALDH1A1SCN9ABRD4TSHR | |
| SCHEMBL4841342 | 0.84 | MAPK14 (0.40) | MAPK14MAPK11 | |
| SCHEMBL14018983 | 0.84 | MAPK14 (0.40) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | MAPK14 70/4885SMN1; SMN2 2168/4885ALDH1A1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.